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Purpose: To investigate the effect of β-glucuronidase on the extraction efficiency of silymarin (mainly as 
silybin) from spiked human plasma using a sensitive and reproducible high performance liquid 
chromatography (HPLC) method.  
Methods: The importance of β-glucuronidase was evaluated by comparing the extraction efficiency of 
silymarin in β-glucuronidase-treated and untreated plasma samples. Isocratic HPLC with simple UV 
detection (288 nm) was applied to analyze the major silymarin components using Thermo-Electron C18 
column (200 mm, 4.6 mm I.D., 5µm particle size). The mobile phase, consisting of methanol and 20 mM 
potassium dihydrogen phosphate buffer (50:50 v/v pH 2.8), was pumped at 1 ml/min.  
Results: The mean extraction efficiency was 98.97 % (CV = 1.69 %) for treated and 40.88 % (CV = 
2.77 %) for untreated plasma samples, compared with nominal concentrations.  
Conclusion: The studied method showed 60 % reduced extraction efficiency of untreated samples 
compared to treated samples.  
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INTRODUCTION 
 
Silymarin, an extract from the seeds of 
Silybum marianum (milk thistle), has hepato-
protective and free radical scavenging 
activities [1-3]. The principal constituent of 
silymarin is silybin or silibinin, which is a 
mixture of diastereomers, namely, silybin A 
and silybin B (1:1). Other flavonolignans 
present in silymarin extract are isosilybin A, 
isosilybin B, dehydrosilybin, silychristin, 
silydianin, and a few flavonoids, mainly 
taxifolin [4]. Silymarin contains silybin as a 
major component, therefore, most of the 
studies are based on the assessment of 
silybin in plasma [5-7]. Silymarin 
flavonolignans are rapidly metabolized after 
its oral administration and mainly form 
glucuronide conjugates. Major biological 
active components of silymarin are primarily 
present as glucuronide conjugates in human 
plasma [8]. 
 
A suitable analytical technique should be 
simple, sensitive, cost-effective and easy to 
use in analytical laboratories [9,10]. Several 
analytical methods for the detection and 
quantification of silymarin flavonolignans in 
human plasma using HPLC, liquid 
chromatography mass spectrometry (LC/MS), 
and liquid chromatography-electrochemical 
detection have been reported [2-4,8]. These 
techniques, except HPLC, require several 
sample processing steps or derivatization 
[11].  The accuracy and precision of plasma 
analysis of drugs is based upon their 
extraction efficiency from plasma matrix.  
 
In previously reported analytical methods, β-
glucuronidase was applied to free the 
conjugated silymarin components for its easy 
and reproducible detection because the 
conjugation and diastereomeric form 
complicate its quantification from plasma 
samples [2,3]. Therefore, the present study 
was aimed at investigating the effect of β-
glucuronidase on extraction efficiency of 
silymarin from plasma by quantification of its 
major constituent, silybin. This approach has 
not been previously reported in the literature, 
to the best of our knowledge. A previously 
reported HPLC method [2,3], with slight 
modification was validated to assess its 
sensitivity, efficiency, reproducibility, and then 
applied to analyze β-glucuronidase-treated 
and untreated silymarin plasma samples. The 
ultimate purpose was to explore the feasibility 
of using β-glucuronidase to aid the analysis 
silymarin in human plasma and to report a 
simple and reliable HPLC-UV analytical 





Chemicals and reagents 
 
Silymarin was a kind gift from Amson 
Vaccines & Pharma (Pvt) Ltd, Islamabad, 
Pakistan. β-glucuronidase/arylsulfatase, 
methanol, potassium dihydrogen phosphate, 
phosphoric acid, sodium acetate, glacial 
acetic acid, boric acid, potassium chloride, 
sodium hydroxide and diethyl ether were 
obtained from Merck-Germany. Double 
distilled de-ionized water was prepared in our 
laboratory.    
 
Chromatographic conditions and 
instrumentation 
 
Analyses were performed using high 
performance liquid chromatography (HPLC) 
with an isocratic pump and variable 
wavelength detector (Agilent Technologies, 
series 1100, USA). A reversed phase system 
was used, consisting of C18 column (200 mm, 
4.6 mm I.D., 5 µm particle size). The mobile 
phase consisted of a mixture of methanol and 
20 mM potassium dihydrogen phosphate 
buffer (50:50, v/v), with the pH of the buffer 
adjusted to 2.8 with phosphoric acid. The 
mobile phase was filtered through a 0.45µm 
membrane filter before use and then pumped 
at a rate of 1 ml/minute; sample volumes of 
100 µl were injected, with a total run time of 
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Stock solutions and spiking of plasma 
 
The stock solution of silymarin was prepared 
fresh by dissolving 50 mg drug in 50 ml of 
methanol to give a final concentration of 1 
mg/ml (1000 µg/1000 µl). Working solutions 
of Silymarin were prepared in mobile phase, 
by appropriate dilution to obtain solutions with 
concentrations of 2.5, 15, 30, 62.5, 125, 250 
and 500µg/ml. 
 
A calibration curve was constructed by 
spiking 1ml plasma samples each with 20 µl 
of one of the above mentioned working 
solutions to produce concentrationsts 
equivalent to 0.05, 0.3, 0.6, 1.25, 2.5, 5.0 and 
10 µg/ml of silymarin. Volumes of 100 µl were 
injected and the peak areas were recorded 
for each concentration. Five sets of samples 
in human plasma were prepared in duplicate 
(treated with β-glucuronidase and untreated 
samples) at concentrations of 0.05, 0.3, 0.6, 




The extraction procedure for β-glucuronidase 
treated plasma samples, comprised of 100µl 
aliquot of acetate buffer (pH 5.6) and 30 µl of 
β-glucuronidase (glucuronidase/arylsulfatase 
mixture, type HP-2, 127,300 units/ml, Helix 
Pomatia), were added to 100 µl plasma 
samples. The mixtures were incubated with 
periodical shaking at 37 
O
C for 2 h. 
Thereafter, 200 µl of borate buffer (pH 8.5) 
and 2.0 ml of diethylether were added, and 
vortex mixed of 1 min and centrifuged at 
3000 rpm for 2 min. The organic phase was 
transferred into a clean sample test tube and 
evaporated under a gentle stream of 
nitrogen. The dried residues were 
reconstituted in 130 µl of mobile phase, 
vortexed for 30 s and centrifuged for 1 min at 
2500 rpm. Finally, 100 µl of this solution was 
injected directly into the chromatographic 
system. The same extraction procedure was 
applied to prepare untreated plasma 
samples, except that β-glucuronidase was 
not added. Incubation conditions (37 
0
C for 2 
h) were the same as for the treated samples. 
Method validation  
 
Validation was performed in accordance with 
the current Food and Drug Administration 
(FDA) guidelines for biological method 
validation [12]. The validation run comprised 
a set of calibration samples, β-glucuronidase-
treated and untreated silymarin plasma 
samples to determine analytical differences in 
β-glucuronidase cleavage of conjugates in 
human plasma samples. All the validation 
parameters were compared for treated and 




Plasma was collected from human healthy 
subjects. The study was approved by the 
Pharmacy Research Ethics Committee 
(PREC), Faculty of Pharmacy and Alternative 
Medicine, The Islamia University of 
Bahawalpur and the guidelines of 
International Conference on Harmonization 
(ICH) were followed in the study [13]. The 
plasma was spiked with prepared working 
dilutions of silymarin in the range of 0.05 − 
10.0 µg/ml. All spiked samples were 
extracted and analyzed by HPLC. The 
calibration curve was constructed by plotting 
the peak areas versus extracted 
concentrations of silymarin. Six replicate (n = 
6) tests were carried out at each level. 
Linearity of the method was assessed by 
applying least-squares regression lines. 
Linearity was expressed by correlation 
coefficient (r
2
), slope and intercept, which 
were computed using Microsoft Excel 2007 
and confirmed by Kinetica
®
 PK/PD version 
4.4.  
 
Precision and accuracy 
 
Repeated injections (n = 6) were performed 
to assess the repeatability (intra-day) and 
reproducibility (inter-day) for establishing the 
precision and accuracy levels. The inter-day 
and intra-day coefficients of variation were 
recorded as %CV. Accuracy was measured 
as percentage from spiked quantity of drug, 
using Eq 1.  
% Accuracy = (Co/Cs) x 100 ……………… (1)  
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where Co is the observed concentration 
(quantitated after extraction) and Cs is spiked 
concentration (theoretical quantity added). 
 
Limit of detection (LOD) and limit of 
quantitation (LOQ) 
 
Limit of detection (LOD) and limit of 
quantitation (LOQ) were determined to 
establish the sensitivity of the analytical 
method. LOD is repeatedly detected lowest 
analyte concentration while LOQ refers to 
reliably quantitated lowest concentration 
under specified experimental conditions. LOD 
and LOQ were determined by repeatedly 
injecting (n = 6) the samples from the lowest 
to the highest concentration accurately and 




Extraction efficiency was determined by 
adding known concentrations of silymarin to 
prepare spiked solutions and comparing their 
responses (peak areas) to that of pure 
standard solutions (non-extracted). Three 
sample batches were prepared and subjected 
to measure their extraction efficiency. These 
sample batches comprised of the following 
silymarin concentration ranges: Batch-01 
(0.05 − 10.0 µg/ml, same as for calibration 
curve), Batch-02 (0.05, 0.3, 0.6, 2.5, and 5.0 
µg/ml, for treated samples), and Batch-03 
(0.05, 0.3, 0.6, 2.5, and 5.0 µg/ml), for non-
treated samples). 
 
Freeze thaw stability  
 
Stability studies of plasma samples (for both 
spiked plasma and drug free blank plasma 
sample which served as control) were 
performed in three freeze-thaw cycles (cycle 
0, cycle 1, cycle 2 and cycle 3 and each cycle 
consisted of 72 h). All the samples were 
stored at -70 
o
C in ultra-low freezer (Sanyo, 
Japan) for 72 h, and freeze-thaw stability was 
determined as percent recovery (n = 3). The 
stored samples were withdrawn from the 
ultra-low freezer and allowed to thaw at room 
temperature in ordinary light. The thawed 
samples were assayed for silymarin content. 
Statistical analysis 
 
Statistical analysis was performed to 
determine significant differences (if any) 
between the extracted silymarin contents of 
treated and untreated plasma samples. The 
data were analyzed using MedCal software, 





Linearity, precision and accuracy 
 
The linearity of the method was investigated 
within the concentration range of 0.05 – 10 
µg/ml. The applied method showed good 
linearity under the described optimum 
chromatographic conditions. The linear 
regression equation was y = 47.09x + 16.48 
with a correlation coefficient (R²) of 0.9909. 
Retention times were 13.296 and 14.895 for 
silybin A and silybin B, respectively. A 
representative chromatogram is shown in Fig 1. 
 
                               Time (min) 
                     
Fig 1: Representative chromatogram of silymarin 
in treated plasma 
 
Intra-day and inter-day precision and 
accuracy results for the method are shown in 
Table 1. Intra-day precision of silymarin (at 
low, mid and highest concentration levels of 
0.05, 1.25 and 5 µg/ml) ranged from 1.6 - 2.3 
%, expressed as percent coefficient of 
variation (%CV), while accuracy was > 99 %. 
Inter-day precision and accuracy were 1.8 - 
2.8 % (expressed as %CV) and > 98 %, 
respectively. %CV was within the acceptable  
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Concentration found Precision (%CV) Accuracy (%) 
Intra-day    
0.05 0.048 ± 0.001 2.292 96.00 
1.25 1.249 ± 0.021 1.697 99.92 
10 9.994 ± 0.171 1.711 99.94 
Inter-day 
0.05 0.047 ± 0.001 2.766 94.00 
1.25 1.237 ± 0.022 1.811 98.96 
10 9.868 ± 0.214 2.169 98.68 
 




Conc. found in treated 
samples (Mean±SD) 
(µg/ml) 
Conc. Found in untreated 
samples (Mean±SD) (µg/ml) 
0.05 0.049 ± 0.0011   ND*
, s
 
0.30 0.297 ± 0.0037 ND
s
 
0.60 0.590 ± 0.0115 0.2402 ± 0.0113
s
 
2.5 2.495 ± 0.0614 0.9935 ± 0.0211
s
 
5 4.986 ± 0.139 2.143 ± 0.0316
s
 
%CV  1.689 2.768 
Extraction efficiency 98.97 % 40.88 % 
*Not detected; s = significant difference between drug concentration of treated and  non-treated samples  (p < 0.05) 
 
limit of 20 % for lower limit of quantification 
and 15 % for upper limit of quantification [12]. 
 
Limits of detection (LOD) and of 
quantitation (LOQ)  
 
LOD and LOQ for silymarin samples (treated 
samples) were 0.028 and 0.05µg/ml, 
respectively. For LOQ, coefficient of variation 




Extraction efficiency was determined as the 
mean extraction efficiency (mean ± SD) of 
treated samples (n = 6). The results obtained 
are shown in Table 2. The mean extraction 
efficiency at nominal concentrations of 0.05, 
0.30, 0.60, 2.5 and 5.0 µg/ml was 98.97 % for 
treated silymarin plasma samples and 40.88 
% for untreated samples. At these 
concentration levels, coefficient of variation 
(%CV) was 1.689 and 2.768% for treated and 
untreated samples, respectively. 
 
The studied method showed approximately 
60 % reduced extraction efficiency compared 
with untreated samples.  
 
Freeze-thaw stability  
 
Freeze-thaw stability was determined as 
percent recovery (mean ± SD) compared to 
nominal concentrations in plasma samples. 
The difference in nominal value was in range 
of -1.6 to -7.8 % at the completion of the third 




The rapid and simple analysis of compound 
drug with complex constituents (plant based 
drugs) is often difficult to carry out with 
reasonable accuracy and precision. 
Analytical    quantification   of   such    drugs 
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Table 3: Freeze-thaw stability in plasma for silymarin (treated samples). 
Freeze-Thaw Cycles 


























CV (%) 1.292 1.375 1.448 1.787 1.529 1.920 1.588 1.997 
%Difference - - -1.622 -1.497 -4.511 -5.199 -6.792 -7.849 
 
becomes more complicated when they are 
analyzed in biological fluids such as human 
plasma [14-15]. This might be because of 
interference caused by plasma protein 
binding as well as difficult in recovering drug 
from plasma matrix. The test method is a 
slightly modification of previously reported 
methods [2,3] and has been validated to 
analyze silymarin in human plasma 
irrespective of the dosage forms.  
 
The present method was successfully 
validated to authenticate its sensitivity, 
reproducibility, precision and accuracy in 
order to explore the effect of β-glucuronidase 
on the recovery of silymarin from plasma 
samples. Various mobile phases of 
acetonitrile and methanol with different buffer 
solutions (acetate, citrate and phosphate 
buffer) were tested in preliminary 
experiments to ascertain the optimum for 
maximum separation, sensitivity and 
reproducibility. The mobile phase of 
methanol: phosphate buffer (50:50, v/v) at pH 
2.8 with 1 ml/min flow rate provided optimum 
separation. The intra-day and inter-day 
variability of the studied method was 
minimum (< 2.3 %) at low, mid and highest 
concentrations of silymarin of 0.05, 1.25 and 
5 µg/ml, respectively, while accuracy was > 
99 %.  
 
This validated and optimized method was 
applied to explore the effect of β-
glucuronidase in the extraction recovery of 
silymarin from human plasma. The samples 
extracted after treatment with β-
glucuronidase showed an apparent difference 
in silymarin quantitation with high sensitivity 
and better response (peak areas and heights) 
as compared to non-treated samples. The 
mean extraction efficiency was 98.97% (%CV 
as 1.689%) for treated and 40.88% (%CV as 
2.768%) for non-treated plasma samples 
when compared with nominal concentrations.  
The biological fluids such as plasma, urine 
are a complex mixture of biomolecules that 
can interfere with the analysis of drugs by 
reducing extraction efficiency or by 
complicating the separation of analytes at the 
selected UV wavelength. Efficient extraction 
process during sample preparation can 
recover specific analytes of interest by 
treating with suitable precipitating agents 
and/or compounds which make the spiked 
drug free from plasma matrix. 
β-glucuronidase is used in HPLC method 
development process for silymarin analysis 
and, in this method can be applied to quantify 
the silymarin in plasma samples after oral 
administration. These samples are treated 
with β-glucuronidase to cleave the major 
glucuronide conjugates (substrate for β-
glucuronidase) of silymarin to free the drug, 
and this make its detection and quantitation 
easy. 
 
Silymarin conjugates with glucuronide and 
sulfate both in-vitro and in-vivo [8]. The 
glucuronidation was extensive conjugation 
because of the fact that glucuronic acid is 
readily available, derived from glucose and is 
stored in the form of glycogen. Agents with 
functional groups such as hydroxyl, amino, 
carboxyl and sulfhydryl have a high binding 
affinity for glucuronic acid. Glucuronidation is 
catalyzed by UDP-glucuronosyltransferases, 
which are located in endoplasmic reticulum, and 
most dominant enzymes [16]. In our study, we 
found decreased response to silymarin 
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detection and quantification in untreated 
samples, as the silymarin was completely 
undetected at 0.05 and 0.30 µg/ml. The 
reduced silymarin recovery from spiked plasma 
(untreated) can be attributed to gucuronidation 
or sulfation following incubation. β-
glucuronidase treatment cleaved these 
conjugates which increased free drug 
concentration and extraction recovery from 




The studied method is suitable for accurate, 
precise and reproducible quantification of 
silymarin without interference from 
endogenous components of plasma. This 
method can be applied for the 
pharmacokinetic analysis and therapeutic 
monitoring of silymarin in human plasma with 
high sensitivity and resolution, by treating 
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